Eli Lilly and Company's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
Posted:
FDA has authorized bebtelovimab for emergency use for certain non-hospitalized patients with mild-to-moderate COVID-19 at high risk of progression to severe disease for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate Bebtelovimab neutralizes Omicron as demonstrated by pseudovirus and authentic virus data.
Generative AI voice agents—conversational systems powered by large language models that can understand and produce natural speech in real time—are poised to transform how health systems engage with patients.
Read more here.
Stanford Medicine researchers developed a way to create the first heart and liver organoids that generate their own blood vessels, possibly paving the way for organoid-based regenerative therapies.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us